Polypeptide-based micelles for delivery of Irinotecan: Physicochemical and in vivo characterization

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 1947-1956

  Ramasamy, Thiruganesh ^a   Choi, Ju Yeon ^a   Cho, Hyuk Jun ^a   Umadevi, Subbaih Kandasamy ^b   Shin, Beom Soo ^c   Choi, Han Gon ^d   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b OSMANIA UNIVERSITY   (India)

^c Catholic University of Daegu   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Anticancer; Block ionomer complex; Irinotecan; Polypeptide; Self assembly

Indexed keywords

IRINOTECAN; MACROGOL; PHOSPHATE BUFFERED SALINE; POLYASPARTIC ACID; POLYPEPTIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE; POLYETHYLENE GLYCOL-BLOCK-POLYASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL VIABILITY; CHEMICAL INTERACTION; CIRCULATION TIME; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DISPERSION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELIMINATION RATE CONSTANT; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MICELLE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; POLYMERIZATION; PRIORITY JOURNAL; STATIC ELECTRICITY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; X RAY ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOPARTICLES; NEOPLASMS; POLYETHYLENE GLYCOLS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934950009     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1588-8     Document Type: Article

References (40)

1. Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm. 2007;67:9-17.
2. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93-107.
3. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, et al. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedine Nanotechnol Biol Med. 2010;6:478-85.
4. ZhangH,Wang J,MaoW, Huang J,WuX, She Y, et al.Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies. J Control Release. 2013;166:147-58.
5. Tobin P, Rivory L, Clarke S. Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Clin Pharmacol Ther. 2004;76:505-6.
6. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer. 1999;35:371-9.
7. Zhang L, Cao DY, Wang J, Xiang B, Dun JN, Fang Y, et al. PEG coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals. Eur Rev Med Pharmacol Sci. 2013;17: 3347-61.
8. Guo S, Zhang X, Gan L, Zhu C, Gan Y. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2). J Pharm Pharmacol. 2010;62:973-84.
9. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev. 2011;63:184-92.
10. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008;14:1888-96.
11. Kim JO, Ramasamy T, Yong CS, Nukolova NV, Bronich TK, Kabanov AV. Cross-linked polymeric micelles based on block ionomer complexes. Mendeleev Commun. 2013;23:179-86.
12. Mishra D, Kang HC, Bae YH. Reconstitutable charged polymeric (PLGA)(2)-b-PEImicelle for gene therapeutics delivery. Biomaterials. 2011;32:3845-54.
13. RiessG. Micellization of block copolymers. Prog Polym Sci. 2003;28: 1107-70.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
15. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kataoka K. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target. 1997;7:171-86.
16. Alakhov VY, Klinkski E, Li S, Pietrzynski G, Venne A, Batrakova E, et al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials.Colloid Surf B Biointerfaces. 1999;16:113-34.
17. Kim JO, Kabanov AV, Bronich TK. Polymer micelles with crosslinked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009;138:197-204.
18. Bronich TK, Popov AM, Eisenberg A, Kabanov VA, Kabanov AV. Effects of block length and structure of surfactant on self-assembly and solution behavior of block ionomer complexes. Langmuir. 2000;16:481-9.
19. Oh KT, Bromberg L, Hatton TA, Kabanov AV. Block ionomer complexes as prospective nanocontainers for drug delivery. J Control Release. 2006;115:9-17.
20. Tian Y, Bromberg L, Lin SN, Hatton TA, Tam KC. Complexation and release of doxorubicin from its complexes with Pluronic P85-bpoly(acrylic acid) block copolymers. J Control Release. 2007;121: 137-45.
21. Tian Y, Ravi P, Bromberg L, Hatton TA, Tam KC. Synthesis and aggregation behavior of Pluronic F87/poly(-acrylic acid) block copolymer in the presence of doxorubicin. Langmuir. 2007;23:2638-46.
22. Ramasamy T, Kim J, Choi HG, Yong CS, Kim JO. Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J Biomed Nanotechnol. 2014;10: 1304-12.
23. Ramasamy T, Khandasami US, Ruttala H, Shanmugam S. Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent. Macromol Res. 2012;20:682-92.
24. Ramasamy TG, Haidar ZS. Characterization and cytocompatibility eval-uation of novel core-shell solid lipid nanoparticles for the controlled and tunable delivery of a model protein. J Bionanosci. 2012;5: 143-54.
25. Silverstein RM, Bassler GC, Morrill TC. Spectrometric Identification of Organic Compounds. 5th ed. NY: John Wiley & Sons; 1991. p. 91-142.
26. Shu S, Zhang X, Teng D, Wang Z, Li C. Polyelectrolyte nanoparticles based on water-soluble chitosan-poly(L-aspartic acid)-polyethylene glycol for controlled protein release. Carbohydr Res. 2009;344: 1197-204.
27. Blume A, Hubner W, Messner G. Fourier transform infrared spectroscopy of 13C=O-labeled phospholipids hydrogen bonding to carbonyl groups. Biochemist. 1988;27:8239-49.
28. Dicko A, Tardi P, Xie X, Mayer L. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm. 2007;337:219-28.
29. Ramasamy T, Tran TH, Choi JY, Cho HJ, Kim JH, Yong CS, et al. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr Polym. 2014;102: 653-61.
30. Torchilin VP. PEG-based micelles as carriers of contrast agent for different imaging modalities. Adv Drug Deliv Rev. 2002;54:235-52.
31. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J PharmSci. 2009;37:508-13.
32. Ramasamy T, Tran TH, Cho HJ, Kim JH, Kim Y, Jeon JY, et al. Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm Res. 2014;31:1302-14.
33. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann NY Acad Sci. 2000;922:1-10.
34. Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style. Biomaterials. 2010;31:1360-71.
35. Assumpçao JU, Campos ML, Ferraz Nogueira Filho MA, Pestana KC, Baldan HM, FormarizPilon TP, et al. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin. J Pharm Sci. 2013;102:289-96.
36. Lee Y, Lee H, Kim YB, Kim J, Hyeon T, Park H, et al. Bioinspired surface immobilization of hyaluronic acid on monodisperse magnetite nanocrystals for targeted cancer imaging. Adv Mat. 2009;20: 4154-7.
37. Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol. 2011;670:372-83.
38. Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation life-times of tissue plasminogen activator. Biomaterials. 2009;30:5751-6.
39. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release. 2008;127:41-9.
40. Mendoza AEH, Préat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011;156:421-6.